CN100594937C - Stable injection composition and method therefor - Google Patents
Stable injection composition and method therefor Download PDFInfo
- Publication number
- CN100594937C CN100594937C CN200510067324A CN200510067324A CN100594937C CN 100594937 C CN100594937 C CN 100594937C CN 200510067324 A CN200510067324 A CN 200510067324A CN 200510067324 A CN200510067324 A CN 200510067324A CN 100594937 C CN100594937 C CN 100594937C
- Authority
- CN
- China
- Prior art keywords
- pfc
- liquid
- granule
- suspension
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 25
- 238000002347 injection Methods 0.000 title abstract description 14
- 239000007924 injection Substances 0.000 title abstract description 14
- 238000000034 method Methods 0.000 title description 13
- 239000011521 glass Substances 0.000 claims abstract description 41
- 239000007788 liquid Substances 0.000 claims abstract description 41
- 239000008187 granular material Substances 0.000 claims description 53
- 239000000725 suspension Substances 0.000 claims description 49
- 239000002245 particle Substances 0.000 claims description 21
- 239000001506 calcium phosphate Substances 0.000 claims description 17
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 17
- 235000011010 calcium phosphates Nutrition 0.000 claims description 17
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 17
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 7
- 239000001527 calcium lactate Substances 0.000 claims description 7
- 235000011086 calcium lactate Nutrition 0.000 claims description 7
- 229960002401 calcium lactate Drugs 0.000 claims description 7
- 239000004531 microgranule Substances 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 18
- 239000000243 solution Substances 0.000 abstract description 12
- 230000000975 bioactive effect Effects 0.000 abstract description 5
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 40
- 239000000843 powder Substances 0.000 description 34
- 229960005486 vaccine Drugs 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 18
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 18
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 12
- 229950011087 perflunafene Drugs 0.000 description 12
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000006641 stabilisation Effects 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- BTRWUZQEZSPCPS-UHFFFAOYSA-N 1,2,3,4,5,6,7,8,9,10-decafluorophenanthrene Chemical compound FC1=C(F)C(F)=C2C3=C(F)C(F)=C(F)C(F)=C3C(F)=C(F)C2=C1F BTRWUZQEZSPCPS-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- -1 hydroxyl isomaltulose Chemical compound 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004434 industrial solvent Substances 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- PCIUEQPBYFRTEM-UHFFFAOYSA-M 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoate Chemical compound [O-]C(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PCIUEQPBYFRTEM-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000615 nonconductor Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229960004624 perflexane Drugs 0.000 description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229920006926 PFC Polymers 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940124508 injectable medicine Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000007578 melt-quenching technique Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940013883 sucrose octaacetate Drugs 0.000 description 1
- 229940089453 sudafed Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 229960001515 yellow fever vaccine Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
A stable liquid injection contains the first component which is the saccharide (or phosphate) glass microparticles containing the bioactive substances, and the second component which is the biocompatible carbon perfluoride solution, in which said the first component is dispersed, but not dissolved.
Description
The application divides an application for Chinese patent application No.00819965.5 (PCT/US00/28244's).
Background technology of the present invention
Vaccine or the drug solution of preparing injection are original just unstable, need cold preservation.Traditional pharmaceuticals industry overcomes this problem of unstable by medicine is carried out lyophilization.Do very waste, inconvenience like this and have certain danger inherently, this is maybe may cause solution to pollute because the wrong reconstruct of dry drug may cause dosage to make a mistake.A century in the past, carried out many effort develop dense, stable, be equipped with injection liquid preparations, but it's a pity not success.Only born firm small-molecule drug may reside in the aqueous solution and has the useful storage life.
This problem is especially sharp-pointed in vaccine industry.During by 2005, estimate that the employed vaccine dose in the whole world can reach 3,600,000,000.The World Health Organization (WHO) has stated and can not use standard vaccine preparation (" change of immunization " (the Revolutionizing Immunizations) that all needs cold preservation in all, Jodar L., Aguado T., Lloyd J. and LambertP-H.Genetic Engineering News on February 15th, 1998).That use at present is " cold-chain (the cold chain) " of cold storage, and it can be transported to it in cities and towns of developing world from vaccine factory.For the health tissues of vaccine enterprise and non-government property, it is huge utilizing cold-chain to carry out immune active cost.WHO estimates that maintenance cost every year of this cold-chain is more than 200,000,000 dollars.In addition, the immunity activity only can be arrived near the people of these last links of living in this cold-chain.
The people that vaccine motion need be carried out medical training is to guarantee the correct sign of dosage being injected and occurred degraded.Some vaccines such as measles, yellow fever and BCG vaccine need be reconstructed, and this also is the problem that need pay close attention in the art.Must accurately operate with the correctness of guaranteeing dosage and in the process of operation and also may introduce potential polluter, this usually can cause calamity clinically.In addition, because owing to the chemical incompatibility of some component makes it to obtain particular mixtures or " multivalence " vaccine, so the vaccine more than usually needing to give once in a period, this may need to carry out multiple injection.WHO by positive encouragement study with obtain not need cold preservation and do not need the stabilization of vaccines of future generation of reconstruct emphasized these problems (" pre-single dose injection device of filling: a kind of safety standards of novel vaccine; or change that immune material transmits? " (Pre-Filled Monodose Injection Devices:A safety standard for new vaccines, ora revolution in the delivery of immunizations?), Lloyd J. and Aguado M.T., WHO publishes, in May, 1998." general policy problem: injectable solid vaccine: the role in following immunization? " (General Policy issues:injectable solidvaccines:a role in future immunization?), Aguado M.T., J6dar L., Lloyd J., Lambert P.H., WHO publication No.A59781).
A kind of ideal solution of this problem provides the preparation that a kind of completely stable remarks are penetrated.Such stable vaccine may be packaged in becomes independently dosage in the injection device itself, perhaps, for a large amount of immunity is movable, can be transported with the form of larger capacity, does not have the jet injector of syringe needle to carry out administration by a kind of then.Relevant for do description (Sarphie DF, Burkoth TL, the method for use compact substance particulate composition in the percutaneous granule transmits that solid percutaneous transmits by the gas jet injection.PCT publication number WO9748485 (1996)); the percutaneous of dried dna vaccination inoculation obviously very effective (" the hepatitis B dna vaccination of PowderJect is the protection immunoreation that has caused the people of success for the first time " (PowderJect ' s Hepatitis B DNA Vaccine First To Successfully ElicitProtective Immune Response In Humans), http://www.powderject.com/pressreleases.htm (1998)).
The helium supersonic speed shock wave that can be used to drive these powder syringes has limited strength, so fine grain dosage can not be carried out the intramuscular transmission.This is because low-quality granule can not obtain the required enough momentum of deep infiltration.Be enough to obtain good immunogenicity though be coated on the percutaneous transmission of the dna vaccination on the aurosol granule, carry out auxiliary common vaccine with insoluble aluminum or calcium salt and can induce unacceptable skin irritation.They must be by intramuscular administration.Required is a kind of can from intradermal to the flexiblesystem that gos deep into transmitting in the intramuscular transmission depth bounds, its degree of depth that can transmit is similar to the degree of depth that can reach with existing pin and injector technology.For a large amount of immunity were movable, this a kind ofly can impel narrow flow of liquid (liquid jet syringe of diameter~0.15mm) enter into " liquid fingernail " has obtained solution, and it uses about 3, the pressure of 000psi by developing.This device can be by on epidermis, passing small hole painless with its dosage by skin-communication in deep subcutaneous or muscular tissue.Provide high momentum the degree of depth to infiltrate for this flow of liquid to guarantee it.Up to now, the medicine of injection and vaccine always are based on water, but because problem of unstable discussed above, and the scope of stabilized aqueous product that can be used for this technology is very limited.
Have realized that now many bioactive molecules by sugar on glass carry out drying and can be stabilized (Roser B. " protections of protein etc. " the UK patent No. is 2,187,191.Roser B and Colaco C. " the biology macromolecular substances and the stabilisation of other organic compound " PCT publication number WO 91/18091.Roser B. and Sen S. " glass of new stabilisation " PCT number of patent application is: 9805699.7,1998 years).These exsiccant stable active substances are not subjected to the influence of hostile environment such as high temperature and ionizing radiation.
Sugar is gamma transition to the remarkable stabilizing mechanism of molecule.When the sugar juice that will comprise bioactive molecule carried out drying, it can crystallize out when reaching the solubility limit of sugar, maybe can become oversaturated syrup.The crystalline ability of sugar opposing is a kind of critical nature of good stabilizing agent.Trehalose has good properties (Green JL.﹠amp in this respect; Angel CA. " phase relationship in the sucrose solution and vitrification and trehalose unusual " .J.Phys.Chem.93 2880-2882 (1989)) but be not unique.Progressively drying makes this sugar constantly solidify further, becomes a kind of glass under low residual moisture content.This active component liquid solution from water unawares becomes solid solution in the sugared glass of doing.Chemical diffusion in glass is negligible, has therefore in fact stopped chemical reaction.Because Denaturation is a kind of chemical change, it can not take place in glass, so can be with the molecule stabilisation.If can satisfy a kind of other condition, the molecule that exists with this form does not still change.This is a kind of second critical nature of good stabilizing agent, promptly is chemically inert and does not have active.Many glass can not be with reacting with product between the storage life because of them exactly.Tangible problem can take place in reducing sugar, its can form good physics glass but then in typical Maillard reaction their aldehyde group can attack the amino group of product.This is the main cause that many cryodesiccated medicines need cold preservation.Do not have active sugar can provide stable product, do not need to carry out cold preservation.
The biomolecule that is fixed in the sugared glass also is stable in nonaqueous industrial solvent, these molecules itself and sugar all are that insoluble (Cleland JL. and Jones AJS. " the excipient stabilisation of the polypeptide of handling with the organic solvent " patent No. is 5 in the industrial solvent of this non-water, 589,167 United States Patent (USP) (1994)).Because sugared glass can be used as the barrier of impermeability in the liquid of non-solvent,, the biomolecule in the solid solution of glass do not carry out chemical reaction with solvent and environment so can being protected.If this liquid itself is stable, then the responsive product in the glass particle of suspendible has just been formed a kind of stable biphase liquid preparation.The industrial solvent of the described classification of Cleland and Jones (1994) pines for having limited practicality adding.Substitute with the non-aqueous liquid of bio-compatible and can guarantee even least stable medicine, vaccine and diagnostic reagent can be prepared to stable liquid preparation.
Having designed the stable non-aqueous liquid of the first generation is used for medicine or vaccine transmission (B.J.Roser and S.D.Sen " at the stable granule of liquid preparation " is numbered the PCT patent application of GB98/00817, it has described the powder formulation of the stabilisation glass that comprises active component, and it is suspended in injectable oil such as Oleum sesami, Oleum Arachidis hypogaeae semen or the Oleum Glycines or is suspended in simple ester such as the ethyl oleate.By the hydrophilic of the sugared glass particle of suspendible very strong and oily be hydrophobic.Because aqueous favoring and hydrophobic mutually intensive separation trend, so should tend to assembling together by sugar glass.In order to stablize such " Water-In-Oil " type suspension, usually need to use the oil soluble surfactant that is dissolved in the oil-continuous phase.
The surfactant of these low HLB values (hydrophilic value) gathers on the interface between hydrophilic granule and the oil, and with a kind of amphiphilic layer they is coated, and this amphiphilic layer is more compatible with successive oil phase.Because separated by drying oil between the various sugared glass particles, so the interaction of chemistry can not take place between granule.Therefore, some different particle swarms can be arranged in identical Oily preparation, each particle swarm can comprise different may interactional molecule, they can not interact in this oil formulation.Can produce compound polyvalent vaccine in this way.
But, find that subsequently this method has some shortcomings, make it can not form a kind of general solution.Shortcoming comprises the deposition that mix suspension grain inevitably can take place, and it generally has about 1.5g/cm in the lower oiliness excipient of density
3Density.This patent has admitted this problem and has wished to solve this problem below particulate diameter is reduced to 1 μ m, and reducing particulate diameter is in order to make these granules keep the state of suspendible by thermodynamic force such as Brownian movement.Requiring all particulate diameters is a shortcoming for the preparation of being advised less than 1 μ m all.Obtain so little granule easy task anything but.The spray drying scheme of improvement may can accomplish this point but small grain size will make and can not use the cyclone-type catcher and need a kind of filtration system that product reclaims that be used for.
The size that granule is reduced to submicron in theory also is feasible, can reach this target with high pressure trace homogenizer such as micro-fluidisation device (Constant SystemsInc.) after being suspended in this granule in the oil.So just need carry out extra step, and we find spray-dired sugared glass microsphere pulverized and be not very effective, this is because these granules have spheric shape, so have very high mechanical strength.This just need make it repeatedly by this device.Even so, it is uninfluenced also may to have a lot of bigger granules, therefore need subsequently to filter or settling step to remove these bigger granules.The high viscosity of suspension also makes and is difficult to it is drawn in the syringe in common oiliness excipient, and can only inject slowly when injection.Can not resembling in liquid jet injecting systems, it passes through thin nozzle fast.
Also have been found that, be suspended in the granule in the oil, especially when it comprises a kind of surfactant of low HBL value, it is difficult to be extracted in a kind of aqueous environments subsequently, even after the use buffer washs, they are still astonishing tightly to combine, and this is to cause because be looped around the repellency coating of circumgranular oil.Therefore, need carry out ferocious jolting and mixing or need add more water soluble detergent (having high HBL value specifically) again and enter water so that granule leaves oil phase.When particulate granularity diminished, it is more outstanding that this problem becomes.Last result usually is the blended Emulsion of a kind of confusion rather than a kind of obviously isolating biphase.The release that this problem mainly can cause the slow of active substance and be difficult to expect, rather than required rapid and predictable transmission.External, can make oil float when extracting in the aqueous environments above the water that comprises lysed active substance.This is unacceptable in some situation of external application, as in diagnostic kit or automatic measuring system.At last, but the great majority in the natural oil of the clinical practice that FDA ratified all are easy to suffer the infringement of light degradation, oxidation or other form, need be by careful being stored in the dark environment under relatively low temperature.In addition, they are not chemical inertnesses completely, to such an extent as to they can react slowly with the granule of institute suspendible.
Alliance drugmaker after deliberation the application of powder in noticeable new non-aqueous perfluorocarbon liquids of water-soluble substances (Kirkland WD is used to transmit the compositions and the method for active substance, the patent No. is 5,770,181 United States Patent (USP) (1995)).This piece patent major concern be the function of PFC as the oral contrast reinforcing agent of intestinal diagnosing image.Wherein adding cited water-soluble powder is in order to improve the enhancing of palatability or the PFC contrast effect in gastrointestinal tract.Though do not provide embodiment,, Kirkland perceives these liquid also can be used for drug delivery.In this patent, only enumerated especially stable storing at commercially available powder.We find now, and the active substance of stabilized fragility can be used to produce and very stable can be used for oral and biphase PFC liquid preparation parenterai administration in sugared glass microsphere.This has greatly expanded the Kirkland practical applicability, with its extended to be used for transmitting non-intestinal medicine and vaccine do not need to carry out the preparation that the remarks of any form cold preservation are penetrated.Valuable especially is that low viscosity, high density and the low surface tension of having found PFC makes these stable suspensions to transmit by automaton such as liquid jet syringe.This has opened up two important fields for this technology again, promptly a large amount of immune activity and self-injection.
Perfluocarbon (PFC) is novel, the very stable liquid that is obtained by fluoridizing fully of some organic compound.In fact can not be classified as hydrophilic it or lipophilic, because they substantially all can not mix (Krafft MP ﹠amp mutually with oil except that other PFC and water or other any polarity or nonpolar solvent; The summary of Riess JG. " high fluorizated amphiphile and colloidal dispersion, and their application in biomedical sector.Some contribution.”Biochimie?80?489-5141998)。In addition, they had not both had to participate in and oily hydrophobic interaction, did not have the hydrophilic of participation and water or hydroaropic substance to interact again.As a kind of total result who is separated, the hydrophilic granules piece of being seen being combined in strongly among the PFC in oil generally can not taken place.It can not need surfactant just can make stable suspension, but can use fluorohydrocarbon (FHC) surfactant (Krafft ﹠amp; Riess 1998) and its in PFC liquid, under very low concentration, just have activity.Under these low-down concentration, the FHC surfactant can guarantee that some granule can form perfect monodisperse system, and wherein said granule shows accumulative tendency when not having the FHC surfactant.This PFC liquid itself is not have chemically reactively fully, and this volatile liquid of low-molecular-weight type can not accumulate in body, only is at last to be breathed out along with breathing.
Because be the splendid solvent of gas, so the very special clinical practice that PFC is used in a large number always.They are better than the ability of hemoglobin with the ability of carbon dioxide exchange dissolved oxygen.This has obtained confirmation (GeyerRP, Monroe RG ﹠amp at first at R.P.Geyer in nineteen sixty-eight " depletion of blood rat "; Taylor K. " uses the survival condition of the dabbling rat of perfluocarbon-detergent formulations " fully, Organ Perfusion and Preservation, J.V Norman, J Folkman, L.E.Hardison, L.E Ridolf and F.J.Veith edit .Appleton-Century-Crofts, New York, 85-95 (1968)).At present in some operation process as the commodity Oxygent by name of the water bag PFC type Emulsion form of the alternate selection of confession of human blood blood transfusion
TMThe perfluoro-octyl bromide of (AlliancePharmaceutical Corp.) is assessed.The PFC of liquid form is inhaled into the respiratory distress syndrome that is used for the treatment of premature infant in the lung by suction.
High density and the chemical inertness of also finding them are very valuable.With commodity Vitreon by name
TMThe Decafluorophenanthrene of (Vitrophage Inc.) prevents the withering of intra-operative eye capsule, and it also can make the reattachment of retina that breaks away from.PFC also has been used as the contrast agent of nuclear magnetic resonance (MRI), and for this purpose, has also reported hydrophilic powders to be suspended in wherein to improve its imaging or to make it more agreeable to the taste.(Kirkland W.D. " transmits the compositions and the method for active substance ", and the patent No. is 5,770,181 United States Patent (USP), 1998).This piece patent has also hinted the application of PFC as the continuous phase of transmitting microgranular water soluble drug.Because the number of the at room temperature stable non-intestinal medicine that exists with the dry powder state is limited, so this piece patent is inapplicable for most of injectable medicines.But the stabilisation in the microsphere powder of medicine at sugared glass of describing in Roser and Garcia de Castro (1998) combines with injectable PFCs, makes this technology be applicable to all basically non-intestinal medicine and vaccine.
General introduction of the present invention
The present invention uses a kind of two-phase system as the drug delivery preparation, uses PFC as continuous phase in suspension, and it comprises a kind of discontinuous glassy phase.To obtain density range be about 1.5 to 2.5g/cm thereby be different PFC to be mixed based on the major advantage of the preparation of perfluocarbon
3Final mixture.This make microgranule can be prepared to density matching suspendible liquid so that these microgranules can be from the teeth outwards not floating or deposit to the bottom of container and still can keep the form of stable suspersion.Therefore, different with the preparation based on oil, this preparation does not need the microgranule submicronization is prevented deposition that the microgranule in this preparation can alter a great deal in size.Only be just final particulate diameter to be controlled for the purpose of preparation.The preparation of wanting to be used for pin injection or jet injection can comprise 0.1 to 100 micron granule, or preferred 1 to 10 micron.Do like this and can simplify particulate manufacture method greatly and avoided making very tiny particulate necessity by grinding.Carry out simple dry method after spray drying that can be by routine or the lyophilization or wet grinding prepares granule.When in suspension, needing when highly filled, wish that coating of particles is spherical.Granule in irregular shape " combination " thus can suppress free-flow to together trend is stronger, and spheric granule has inherent " lubricity ", thereby guarantees that solids content can reach more than 20%.Such granule can solidify by spray drying, atomizing freeze drying or Emulsion easily and is prepared.
If preparation is appropriate, the powder of this suspendible does not need surfactant just can produce stable suspension, should the almost dissolving immediately of sugar glass particle when water carries out jolting.If regard a spot of gathering as a problem, then can mix preceding or to mix back useful adding in this PFC liquid a spot of as Krafft and the described FHC surfactant of Riess (1998) will stablizing powder.Similar to PFC, the original inertia of these FHC is just very strong and do not have a reactivity.Therefore, there is not particulate solvation and do not have chemical reaction between mutually at the granule of suspendible and PFC.Because should the sugar glass particle and PFC liquid all be stable in environment, so can be owing to light, high temperature, oxygen or the like are degraded.It has in vivo or the external toxicity that can ignore and the authoritative institution that managed deeply test and ratify can be used as a large amount of being infused in animal and human's body of succedaneum of blood.Though reported that high-molecular weight PFC can gather in liver, low-molecular-weight example used in the present invention uses is all discharged from body when exhaling at last.
Their low surface tension and low viscosity guaranteed they be highly susceptible to by in pin, automatic system or the liquid jet syringe of hypodermic syringe the narrow hole that can run into.PFC is an excellent electrical insulators, therefore is easy to obtain to have particulate single dispersive suspension of identical low surface electrostatic lotus.They are exsiccant, and are complete non-hygroscopic liquid.Their extremely low water content has kept the drying property of suspendible powder, has prevented to be entrained in the dissolving or the degraded of active substance wherein.The solvent properties of their uniquenesses lacks the desirable material that property makes it to become the hydrophilic or hydrophobic granule of suspendible, promptly final suspension in fact can with used any substances compatible in container or the transfer device.This is opposite with preparation based on oil, can cause the serious obstruction of syringe based on the preparation of oil, is for example sealed by the rubber on the piston and expands and cause obstruction.Can obtain various density, vapour pressure and volatile PFC, (Table I).Their high density makes them sink in the buffer that great majority are used always, and this product particle that makes it to be easy to being dissolved in the aqueous phase that swims in the top separates.Therefore, this has promoted it in external application such as diagnostics's application.
The present invention describes in detail
The character of some PFC of Table I
Perfluor-MW density viscosity gauge surface tension vapour pressure
(Kg/L) (mPas) (mN/m) (mbar)
Hexane 338 1.682 0.656 11.1 294
Just-octane 438 1.75 1.27 16.98 52
Decahydronaphthalene 462 1.917 5.10 17.6 8.8
Luxuriant and rich with fragrance 624 2.03 28.4 19<1
In Kirkland (1995), hinted the application of PFC as the excipient that transmits pharmacological agents or bioactive substance.This piece patent only enumerated born stable can the commercial seasoning that obtains or effervescent powder or the like.It does not comprise the bioactive substance of any stabilisation such as the example of vaccine or medicine.In addition, it is not considered by prepare the probability of a kind of injectable (non-intestinal) preparation as the suspendible excipient of active particle with PFC.For obtain a kind of have long pot life with PFC as the stabilization formulations of the fragile biomolecule of this lifes of non-aqueous excipient, preferably this preparation of granules one-tenth is comprised can stablize the form of forming of glass agent of adulterated active substance.Can use various sugar, be included in trehalose described in the PCT application that is numbered WO 91/18091, lactose, hydroxyl isomaltulose (palatinit) or the like or be other more effective monosaccharide sugar alcohol or forming of glass agent described in 9820689.9 the UK patent application more preferably at application number.
For prevent granule swim in compact substance PFC mutually above, useful in this granule, add a kind of density adjuster.It can be salt such as sodium chloride or potassium chloride or the sodium sulfate or the potassium sulfate of solubility, or more preferably is a kind of insoluble material such as barium sulfate, calcium phosphate, titanium dioxide or aluminium hydroxide.Preferred insoluble innocuous substance, this is because the release of a large amount of ion salt can cause sizable local pain and stimulation in body.In some cases, as in bacterin preparation, a part such as adjuvant that this insoluble material can be this active ingredient.This density adjuster can exist with the solid solution form in sugared glass particle or can exist with a kind of form that is suspended in the insoluble granule material in the sugared glass.When carrying out appropriate preparation, the density of this sugar glass particle can be approximately and the PFC density of liquid match, buoyancy is moderate, and neither floating not sedimentation again but still non-caking stable suspendible body.
Because PFC liquid is good electrical insulator, resistivity generally is higher than 10
13Ohm.cm is so the small surface charge on mix suspension grain has significant effects for the stability of suspension.For the gathering that prevents that mix suspension grain from taking place owing to weak short distance power, it preferably is prepared to and comprises and can provide the excipient of weak remaining electrostatic charge such as the form of lysine or aspartic acid for this dried granule.Do like this and can prevent aggregation by guaranteeing particulate electrical charge rejection power, this is to viewed similar in stable colloid.Perhaps, can valuably a spot of FHC surfactant such as perfluoro decanoate be dissolved in the dispersive suspension of formation among the PFC, preferably form monodispersed suspension.
These granules can be prepared in various manners, comprise air-dry, spray drying or lyophilization, and these granules do not need especially little, and can be that a kind of diameter is the particulate heterogeneous mixture of 0.1 μ m to 100 μ m.For some application, even can use millimeter-sized particles.
The application of the suspension that these are stable both had been not limited only to parenteral application listed above, was not limited only to again as cited oral application among the Kirkland (1995).Because the PFC liquid excipient is nontoxic and reactionless active, so it is a kind of ideal excipient that is applicable to mucosa, comprise can be used in the lung, intranasal, ophthalmic, internal rectum and intravaginal administration.This piece patent is provided can make stable, aseptic and non-irritating can be used for even the ability of the preparation of the mucosa transmission of very unsettled medicine or vaccine is quite advanced.Because microorganism can not be grown under the situation that lacks water, so during long term storage and batch applications, this very exsiccant and complete non-hygroscopic PFC liquid also very helps to keep the aseptic of these preparations.
Because being used as propellant in inhalant always, volatile for a long time perfluoro-hydrocarbon and chlorofluorocarbon be used to make medicine can be delivered to the depths of lung, so this stable PFC preparation as described herein is the desirable material that is used to prepare transmit fluid STASIS fine mist of small droplets in the lung.For this application, form in the PFC droplet that discontinuous particulate size by the suspendible phase is very important should not to surpass 1 to 5 μ m, the diameter of preferred 0.1 to 1 μ m.For other mucomembranous surface in being passed to nose and eye, the importance of granule size is weaker a little, and can be as high as the diameter of 100 μ m, even can reach the diameter of several mm.
Description of drawings
Fig. 1
Alkaline phosphatase (Sigma Aldrich Ltd.) is by with sweet mellow wine 33.3%, calcium lactate 33.3% and the gelatin 33.3% (Byco C, Croda Colloids Ltd.) of degraded be basic glass Institute's stabilisation is spray dried to microballoon, and with dry powder or stablizing in perfluorodecalin The form of suspension is stored in 55 ℃. This activity still for about 100% mark value (20 days was 103%, 30 day is 94%). The dry powder that is not suspended among the PFC does not have bigger loss (still So have an appointment 80% activity)
Fig. 2
By in 20% aqueous trehalose, adding calcium phosphate with a kind of commercial lockjaw Toxoid vaccine (#T022 that is provided by Evans Medeva plc friendship) is prepared into density matching Powder. With two fluid nozzles it is sprayed onto and comes freeze drying in the liquid nitrogen, then, with this freeze-drying The microballoon powder in the Labconco drier, carry out freeze drying, between initial dry period Initial shelf temperature is-40 ℃. Injecting usefulness salt solution buffer reconstruct or the work of same dose For behind the ASSIST stabilisation tetanus toxoid vaccine of the anhydrous formulation among oil or the PFC 4,8 During with 12 week, measure the antibody response of six groups of cavys, every group has 10 cavys.
The reaction that is lower than fresh vaccine contrast for the reaction of all drying agents (is not expressed Come), this shows that spray-dired preparation significantly lost immunogenicity. As using the ELISA that catches That measures is such, and dry run does not change this anatoxic antigenicity. This shows is doing Need to do the preservation that more work improves aluminum hydroxide adjuvant when dry.
For the reaction of having carried out the STASIS vaccine of density matching with calcium phosphate (group 3) base The vaccine that is reconstructed with in contrast use buffer on the basis and at oil bag powder-type vaccine In the reacting phase of (group 2) with, and the control-animal of only injecting with non-aqueous excipient (group 4 and 5) do not show reaction.
The description of preferred embodiment
Embodiment 1:
Spray-dired granule in PFC
Granule is with Labplant SD 1 type spray dryer, and with sugar and other excipient, spray drying is prepared by aqueous solution is carried out.Typical formulation is:
A. mannitol 15%w/v
Calcium lactate 15%w/v
In water
B. trehalose 15%w/v
Calcium phosphate 15%w/v
In water
Two fluid nozzles with the liquid pores with 0.5mm internal diameter prepare this granule.Half that find the maximum nozzle throughput is best, and under the condition of the outlet temperature of 135 ℃ inlet temperature and 70-75 ℃ hothouse operated.Come collecting granules with the glass eddy flow, and by in 4 hours, temperature being risen to gradually 80 ℃ and in a vacuum it to be carried out the second time dry.In case cooling is suspended in it among PFC with ultrasonic.Discovery in MSE MK 2 ultrasound rooms, under about 75% power, operate with ultrasonic energy that 30 seconds bursts is provided with the titanium probe or be immersed in carry out in the Decon FS200 Frequency cleaning ultra sonic bath high just enough to 10 minutes operation.
The suspension of gained is monodispersed and by microscopic examination, its spherical glass granule by about 0.5 to 30 μ m particle size range is formed, and its particle mean size is about 10 μ m.Mannitol/granular calcium lactate just rises to the top of this PFC layer in a few minutes, but it just can be disperseed easily again by jolting lightly.Basic and the PFC of the density of trehalose/calcium phosphate granules matches and has formed stable suspension.
With 1,10,20 and the concentration of 40%w/v the spray-dired powder of sugared glass particle is suspended in perflexane, perfluorodecalin and the Decafluorophenanthrene.Find that they can both obtain the monodispersed suspension of the situation of can assembling hardly.In this PFC, add any slight aggregation tendency that 0.1% perfluoro decanoate can suppress from the teeth outwards to be taken place.Find that these suspensions can be easy to the pin by 25g by sucking or spraying.
Embodiment 2:
The stability of the suspension of the enzyme of stabilizationization in PFC
Come spray drying alkaline phosphatase (SigmaAldrich Ltd.) with the Labplant machine as described above.Said preparation comprises the gelatin (Byco C, Croda colloids Ltd.) 33.3% of mannitol 33.3%w/w, calcium phosphate 33.3%w/w and degraded.The form of this exsiccant enzyme with the form of dry powder or the suspension in perfluorodecalin is stored under 55 ℃.When 55 ℃ of times of placing down were higher than 30 days, the enzymatic activity that the enzyme in these prepared microspheres shows was still near 100%, and wherein said microsphere is formed (Fig. 1) by the glass based on mannitol that is suspended in the perfluorodecalin.
Embodiment 3:
Render a service in the body
Carried out the preclinical test of similar formulations with national biological standard product and reference substance association (having passed through accredited laboratory of World Health Organization (WHO)), clinical tetanus toxoid vaccine (being provided by Medeva plc friendship) is provided wherein said similar formulations.The result of this test shows that ability that this stable STASIS preparation makes Cavia porcellus immunity form the serum antibody response of protectiveness is equal to the aqueous vaccine (Fig. 2) based on water.This confirms that suspension in PFC can form and a kind ofly has in vivo and the conventional preparation of penetrating for the remarks of the identical bioavailability of basic liquid preparation with water.
Embodiment 4:
The granule of atomizing freeze drying
This granule is also by being injected to liquid droplets in the liquid nitrogen, then should refrigerated powder carries out drying in a vacuum and is prepared.These granules are lower than spray-dired particulate density, and form pastel when concentration is higher than 20%w/v in PFC.Under lower concentration, they can form monodispersed suspension after ultrasonic.
Used exemplary formulations is:
Material final concentration w/w
A. trehalose 100%
B. trehalose 50%
Calcium phosphate 49.5%
Aluminium hydroxide 0.5%
Embodiment 5:
The hydrophobic granule that grinds
When from the molten state quenching or from the solution of chloroform or dichloromethane during by rapid draing, hydrophobic sugar derivatives sucrose octaacetate and trehalose eight acetates are easy to form glass.They are described (people such as Roser " the solid transmission system of the controlled release of the molecule that is used for wherein being added with and preparation method thereof " publication number is the PCT application of WO 96/03978,1994) as the application of the controlled release matrix of drug delivery.
Trehalose eight acetate powder can be prepared this melt quenching on corrosion resistant plate by melting in Muffle furnace then.Grind with pestle and mortar sheet glass, with the high-speed homogenization machine it is handled it is prepared into a kind of fine powder then gained.With 1 and the concentration of 10%w/v this powder is suspended in perflexane, perfluorodecalin and the Decafluorophenanthrene.Find that they can provide finely disseminated suspension.Find that these suspensions can pass through the 23g pin easily.
Embodiment 6:
Reconstruct in aqueous environments
Because the person's character of soluble sugar glass particle and the character of PFC, the active component that can predict in these suspensions will discharge rapidly in body.The release fully of the active component that comprises in order to prove becomes to comprise with preparation of granules:
Trehalose 20%w/v
Lysine 0.5%w/v
Mordant Blue 9 dyestuff 1%w/v
With method as above said preparation is carried out spray drying, then it is joined the opaque suspension of the navy blue of making 20%w/v in Decafluorophenanthrene and the perfluorodecalin.After adding the water that equates with suspension volume and carrying out jolting, find that in fact all blue dyess all have been released to aqueous phase, form a kind of clarifying cyan coloring layer that swims on the almost colourless PFC, had obvious interface fully aware of between the two.
Embodiment 7:
Do not have reactivity between the granule in suspension
Because each microsphere in the PFC suspension is that other granule is isolated mutually with all physically,, the material that may react do not have any interactional danger so can coexisting as in the variable grain of identical suspension.When this sugar glass was dissolved, these molecules can be met, and react.
In order to prove this point, prepare a kind of two types of particulate suspensions that comprise, a kind of (a) is enzyme---alkaline phosphatase, another kind of (b) is its colourless substrate, the phosphoric acid p-nitrophenyl.
Preparation is:
A) trehalose 10%w/v
Alkaline phosphatase 20U/ml
In 5mM Tris/HCl buffer agent (pH 7.6)
B) trehalose 10%w/v
Phosphoric acid p-nitrophenyl 0.44%w/v
At the 100mM glycine buffer that comprises 1mM zinc chloride and 1mM magnesium chloride
In the agent (pH 10.2)
Discovery comprises that the powder suspension does not form any color reaction in the perfluorodecalin of powder " b " of the powder " a " of 10%w/v and 10%w/v when placing for 3 weeks down for 37 ℃, and remains the suspension of white.
After adding entry and carrying out jolting, then this powder dissolution is in top aqueous phase.Enzyme reaction taking place in a few minutes, the true yellow of right-nitrophenol occurs, all this situation can occur in the sample in 3 weeks of placement in freshly prepd sample and under 37 ℃.
Embodiment 8:
Product in " organization space " model discharges
The behavior that the PFC suspension may take place in order to explain in being expelled to body prepares a kind of model---and transparent hydration organization space, this model are to be prepared by the agarose gel that moves heap 0.2% in the polystyrene ampoule.The perfluorodecalin suspension of 0.1ml embodiment 5 is expelled in this agarose gel with the 25g pin.So just formed the ball of the white of a flat suspension.At ensuing 5-10 minute, surplus afterwards next clarifying PFC ball was upwards carried out in the clarification that begins to become from the bottom of ball of this white.Because enzyme and substrate are owing to the dissolving of this glass particle is released, so they react each other and have produced xanchromatic paranitrophenol, it spreads in whole agarose in ensuing 1 hour then.
Embodiment 9:
Density matching
Generally has about 1.5g/cm by the sugared glass particle that any method obtained (being trehalose) in the seasoning of two kinds of routines
3Density.The density of the perfluocarbon that we tested is generally 1.68 to 2.03g/cm
3(Table I).For this reason, when being prepared to suspension, sugared glass particle tend to float to the PFC layer above, will produce a kind of active component like this can not equally distributed preparation.But, in order to prepare a kind of stable suspension in PFC, can carry out modification to powder, these powder have moderate buoyancy in this suspension, and it is non-rising again neither to sink.It can be realized to wherein adding highdensity material before forming at granule.These highdensity materials can be water miscible or water-insoluble.
Non-water soluble substance
Density is 3.14g/cm
3Orthophosphate tricalcique go through as the adjuvant of vaccine and in fact water insoluble.The prepared powder that comprises about 50% calcium phosphate shows density to be increased, and its density is about 2g/cm
3, and in Decafluorophenanthrene, form stable suspension with 20% solid-state amount.
In PFC, the example that forms the powder of stable suspension when 20% amount of solid comprises:
1
In perfluorodecalin
Material final concentration w/w
A. trehalose 50%
Calcium phosphate 50%
B. trehalose 47.5%
Calcium lactate 10.0%
Calcium phosphate 42.5%
2
In Decafluorophenanthrene:
Material final concentration w/w
Mannitol 18.2%
Inositol 18.2%
Calcium lactate 18.2%
Calcium phosphate 45.4%
Other the non-water soluble substance that always is used to increase density comprises barium sulfate and titanium dioxide.Can use any nontoxic and insoluble material with Suitable Density.
Water-soluble substances
Water soluble salt is as having 2.7g/cm
3The sodium sulfate of density also can be used as density enhancing.Following powder can form stable suspension in perfluorodecalin:
Material final concentration w/w
Trehalose 50%
Sodium sulfate 50%
Can also use other nontoxic highdensity water-soluble substances.Have been found that these preparations can cause discomfort after Cavia porcellus is carried out subcutaneous injection, this may be because the rapid dissolving of the ion salt of high concentration causes.
Embodiment 10:
Density matching is to the effect of the active substance in the suspension
Some vaccine is prepared to and is adsorbed onto as the insoluble gel of adjuvant or the form on the granule.Aluminium hydroxide and calcium phosphate are widely used in this purpose.Their particulate density that just can be used to increase of these insoluble adjuvants own by suspendible.In this case, highdensity material is not inert fully, but in fact can be from solution the adsorption activity macromolecule.Must prove that this absorption is not enough to change this activity.For this point is tested, with the active substance/vaccine of alkaline phosphatase as model.
The solution that is prepared as follows:
The calcium phosphate 10%w/v of adjuvant grade (Superphos Kemi a/s)
Trehalose 10%w/v
ZnCl
2 1mM
MgCl
2 1mM
Alkaline phosphatase 20U/ml
In 5mM Tris HCl buffer (pH 7.6)
Then this solution is fully mixed 10 minutes down so that this alkaline phosphatase is adsorbed on the calcium phosphate at 37 ℃.Centrifugal by calcium phosphate is carried out, supernatant is taken a sample, under the wavelength of 405nm, use substrate---the phosphoric acid p-nitrophenyl is measured the trap change value that its enzyme kinetics is measured per minute.This solution is carried out spray drying, obtain a kind of fine powder.Use said method, in supernatant, any desorption of this enzyme after this powder rehydration is measured.Concentration with 20%w/v is suspended in this powder in the Decafluorophenanthrene, and discovery can form a kind of stable suspension.
Test specimen d
Trap/ minute (405nm)
Initial soln (25 μ l) 0.409
The as above supernatant of gained (25 μ l) 0.034
The powder of rehydration (25 μ l, 20%w/v is in water) 0.425
The as above supernatant of gained (25 μ l) 0.004
The powder in perfluorodecalin of 20%w/v (25 μ l) 0.430
This experimental results show that:
By comprising auxiliary calcium phosphate, particulate density can be complementary with the density of PFC carrier.
Significant desorbing or loss of enzyme activity do not take place in the preparation process.
Embodiment 11:
The STASIS preparation of the mannitol based glass of embodiment 1 is suspended in the perfluorodecalin, filling it into a kind of the operation then goes up in polypropylene aerosol apparatus cleaning, pumping action, this aerosol apparatus is used to transmit oxymetazoline nose Decongestant (Sudafed, Warner Lambert) clinically usually.Two bursts of sprayings of this suspension are delivered to respectively in two nostrils of human volunteer, have required these volunteers that the degree of sense of discomfort is assessed.The volunteer reports does not have discomfort at all.Do not observe side effect after the administration.
Claims (4)
1. pharmaceutical composition; it contains sugared glass granules or metal carboxylate glass granules; described granule carrying active composition; described particle suspension is in liquid; it is characterized in that microgranule has 0.1 to 100 micron diameter; described microgranule and described density of liquid coupling, and described microgranule keeps stable suspersion in liquid, and wherein said liquid is perfluocarbon.
2. compositions as claimed in claim 1 is characterized in that described granule contains inorganic salt as density adjuster.
3. compositions as claimed in claim 2 is characterized in that described inorganic salt is a calcium phosphate.
4. as each described compositions of above-mentioned claim, it is characterized in that described microgranule contains calcium lactate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510067324A CN100594937C (en) | 2000-10-13 | 2000-10-13 | Stable injection composition and method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510067324A CN100594937C (en) | 2000-10-13 | 2000-10-13 | Stable injection composition and method therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008199655A Division CN100339066C (en) | 2000-10-13 | 2000-10-13 | Stable injecta composition and method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679512A CN1679512A (en) | 2005-10-12 |
CN100594937C true CN100594937C (en) | 2010-03-24 |
Family
ID=35066540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510067324A Expired - Fee Related CN100594937C (en) | 2000-10-13 | 2000-10-13 | Stable injection composition and method therefor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100594937C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
-
2000
- 2000-10-13 CN CN200510067324A patent/CN100594937C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1679512A (en) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6190701B1 (en) | Composition and method for stable injectable liquids | |
CN100339066C (en) | Stable injecta composition and method | |
JP2002504090A (en) | Stable particles in liquid formulations | |
EP1750668B1 (en) | Liquids containing suspended glass particles | |
KR102624471B1 (en) | Gas-filled microvesicles | |
CN101784267A (en) | The slow release chitosan capsules that comprises chitosan and phytic acid | |
AU2001211986A1 (en) | Composition and method for stable injectable liquids | |
EP2833914B1 (en) | Adjuvant system for oral vaccine administration | |
EP0966271A1 (en) | Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same | |
CN100594937C (en) | Stable injection composition and method therefor | |
AU2005203369B2 (en) | Pharmaceutical liquid suspensions | |
CN101745126B (en) | Preparation method of water-soluble drug-encapsulated ultrasonic contrast agent | |
EP1452171B1 (en) | Pharmaceutical liquid suspensions | |
JP4027881B2 (en) | Compositions and methods for stable injections | |
JP4382706B2 (en) | Pharmaceutical liquid suspension | |
RU2259817C2 (en) | Composition for delivering stable injectable liquids and method for delivery | |
KR100743442B1 (en) | Pharmaceutical liquid suspension | |
ZA200609158B (en) | Liquids containing suspended glass particles | |
NZ538681A (en) | A pharmaceutical composition comprising active biological ingredient carried by particles that form a stable suspension in a liquid indefinitely | |
NZ525026A (en) | A two-component composition comprising particles of sugar glass and a biocompatible liquid perfluorocarbon | |
RU2003113537A (en) | COMPOSITION FOR DELIVERY OF STABLE INJECTED LIQUIDS AND METHOD OF DELIVERY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100324 Termination date: 20111013 |